The peptide is intentionally designed with unequal potencies across its three targets
The first oral GLP1 pill received FDA approval in December 2025, with introductory pricing as low as $149 per month for the lowest dose
A number of the published studies where increased reflux was shown among GLP-1 users were conducted in populations who have type 2 diabetes
Change (rotate) your injection site with each weekly injection
Long-term GLP-1 safety has been established through multi-year clinical trials showing benefits in cardiovascular outcomes and sustained weight management without cumulative toxicity
Then we order labs: HbA1c and fasting glucose - to identify prediabetes or type 2 diabetes Comprehensive metabolic panel - kidney and liver function Lipid panel - cardiovascular risk picture TSH - thyroid disease can drive weight changes and is often missed Additional markers based on history (insulin, vitamin D, B12, iron studies as indicated) We also screen for sleep apnea, mood disorders, and medication-related weight effects (some psychiatric and antidiabetic medications drive weight gain that's worth identifying before adding another medication on top)
